Supplementary tables: Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations inParkinson’s disease: a systematic review and meta-analysis

<b>These are peer-reviewed supplementary materials for the article '</b><b>Opicapone as an add-on to levodopa for </b><b>reducing end-of-dose motor fluctuations in </b><b>Parkinson’s disease: a systematic review </b><b>and meta-analysis</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Table S</b><b>1</b><b>:</b> Keywords used in the searches of medical databases to identify relevant studies for opicapone for the treatment of patients with Parkinson’s disease<b>Table S</b><b>2</b><b>: </b>Basic characteristics of the studies included in the meta-analysis<b>Aim:</b> To assess the clinical efficacy and safety profile of opicapone (25 and 50 mg once daily) versus placebo. <b>Patients:</b> Levodopa-treated adults with Parkinson’s disease. <b>Material &amp; methods: </b>A systematic review and meta-analysis were conducted. <b>Results: </b>Opicapone provided a greater reduction in the absolute OFF-time, increased the chances of ≥1-h reduction in the OFF-time and ≥1-h increase in the ON-time compared with placebo. Receiving opicapone more often facilitated levodopa dose reduction versus placebo. There were no differences in the occurrence of adverse events (severe and leading to drug discontinuation), but receiving opicapone increased the frequency of dyskinesia. <b>Conclusion:</b> Opicapone demonstrated superior clinical efficacy to placebo, with a comparable general safety profile.